SassariniJPereraMSpowartK, et al.
Managing vulvovaginal atrophy after breast cancer.Post Reprod Health2018;
24: 163–165.
2.
GambaccianiMLevanciniM.Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors. Menopause2017;
24: 316–319.
3.
PaganoT, De RosaPValloneR, et al.
Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study. Menopause2017;
25: 1–6.
4.
US Food and Drug Administration. FDA warns against use of energy-based devices to perform vaginal ‘rejuvenation’ or vaginal cosmetic procedures: FDA Safety Communication (2018).
5.
GordonCGonzalesSKrychmanML.Rethinking the techno vagina: a case series of patient complications following vaginal laser treatment for atrophy. Menopause2019;
26: 1–5.
6.
TadirYGasparALev-SagieA, et al.
Light and energy based therapeutics for genitourinary syndrome of menopause: consensus and controversies.Lasers Surg Med2017;
49: 137–159.
7.
GambaccianiMPalaciosS.Laser therapy for the restoration of vaginal function.Maturitas2017;
5: 10–15.
8.
BlaganjeMŠćepanovićDŽgurL, et al.
Non-ablative Er: YAG laser therapy effect on stress urinary incontinence related to quality of life and sexual function: a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol2018;
224: 153–158.
